Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization

Vaccine

Volumn 30, Issue 18, 2012, Pages 2869-2881

  Schautteet, Katelijn ^a   De Clercq, Evelien ^a   Jönsson, Yannick ^a   Lagae, Stefanie ^a   Chiers, Koen ^a   Cox, Eric ^a   Vanrompay, Daisy ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Chlamydia trachomatis and genital infection; DNA vaccine

Indexed keywords

ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD8ALPHA ANTIGEN; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BACTERIAL SHEDDING; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CERVICAL LYMPH NODE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; CROSS PRESENTATION; DNA IMMUNIZATION; ESCHERICHIA COLI; FEMALE; GENITAL TRACT INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; NONHUMAN; OVARY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; URETHRA; UTERINE CERVIX; UTERINE TUBE; VACCINATION; VAGINA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVAGINAL; ANIMALS; BACTERIAL VACCINES; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; LYMPHOGRANULOMA VENEREUM; PLASMIDS; SWINE; VACCINES, DNA;

EID: 84858998256     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.044     Document Type: Article

References (66)

1. Bébéar C., de Barbeyrac B. Genital Chlamydia trachomatis infections. Clin Microbiol Infect 2009, 15(January (1)):4-10.
2. Gonzales G.F., Munoz G., Sanchez R., Henkel R., Gallegos-Avila G., Diaz-Gutierrez O., et al. Update on the impact of Chlamydia trachomatis infection on male fertility. Andrologia 2004, 36(February (1)):1-23.
3. Stamm W.E. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999, 179(March):S380-S383.
4. Brunham R.C., Kimani J., Bwayo J., Maitha G., Maclean I., Yang C., et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis 1996, 173(April (4)):950-956.
5. Koskela P., Anttila T., Bjorge T., Brunsvig A., Dillner J., Hakama M., et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000, 85(January (1)):35-39.
6. Samoff E., Koumans E.H., Markowitz L.E., Sternberg M., Sawyer M.K., Swan D., et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005, 162(October (7)):668-675.
7. Golden M.R., Whittington W.L., Handsfield H.H., Hughes J.P., Stamm W.E., Hogben M., et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352(February (7)):676-685.
8. Land J.A., Van Bergen J.E.A.M., Morre S.A., Postma M.J. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010, 16(March (2)):189-204.
9. Peipert J.F. Genital chlamydial infections. N Engl J Med 2003, 349(December (25)):2424-2430.
10. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4)):S45-S53.
11. Vanrompay D., Hoang T.Q.T., De Vos L., Verminnen K., Harkinezhad T., Chiers K., et al. Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection. Infect Immun 2005, 73(December (12)):8317-8321.
12. Rask C., Fredriksson M., Lindblad M., Czerkinsky C., Holmgren J. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. APMIS 2000, 108(March (3)):178-186.
13. Cox E., Verdonck F., Vanrompay D., Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 2006, 37(May (3)):511-539.
14. Lyons J.M., Ito J.I., Morre S.A. Chlamydia trachomatis serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model: host factors as major determinants of C. trachomatis mediated pathogenesis. J Clin Pathol 2004, 57(June (6)):657-659.
15. Mayer A, Bachmann PA, Bibrack B, Wittman G. Virologische Arbeitsmethoden; 1974, p. 35.
16. Schautteet K., Stuyven E., Beeckman D.S.A., Van Acker S., Carlon M., Chiers K., et al. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine 2011, 29(February (7)):1399-1407.
17. Arrington J., Braun R.P., Dong L.C., Fuller D.H., Macklin M.D., Umlauf S.W., et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 2002, 76(May (9)):4536-4546.
18. Van Reeth K., Nauwynck H., Pensaert M. Dual infections of feeder pigs with porcine reproductive and respiratory syndrome virus followed by porcine respiratory coronavirus or swine influenza virus: a clinical and virological study. Vet Microbiol 1996, 48(February (3/4)):325-335.
19. Novak M., Moldoveanu Z., Schafer D.P., Mestecky J., Compans R.W. Murine model for evaluation of protective immunity to influenza virus. Vaccine 1993, 11(1):55-60.
20. Van Zaane D., Hulst M.M. Monoclonal antibodies against porcine immunoglobulin isotypes. Vet Immunol Immunopathol 1987, 16(September (1/2)):23-36.
21. Vanrompay D., Cox E., Mast J., Goddeeris B., Volckaert G. High-level expression of Chlamydia psittaci major outer membrane protein in COS cells and in skeletal muscles of turkeys. Infect Immun 1998, 66(November (11)):5494-5500.
22. Devriendt B., Gallois M., Verdonck F., Wache Y., Bimczok D., Oswald I.P., et al. The food contaminant fumonisin B(1) reduces the maturation of porcine CD11R1(+) intestinal antigen presenting cells and antigen-specific immune responses, leading to a prolonged intestinal ETEC infection. Vet Res 2009, 40(July (4)):40.
23. Igietseme J.U., Eko F.O., Black C.M. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines 2003, 2(February (1)):129-146.
24. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(February (2)):149-161.
25. Su H., Morrison R., Messer R., Whitmire W., Hughes S., Caldwell H.D. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis 1999, 180(October (4)):1252-1258.
26. Brunham R.C., Rekart M.L. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008, 35(January (1)):53-54.
27. Igietseme J.U., He Q., Joseph K., Eko F.O., Ananaba G., Campbell A., et al. Role of T lymphocytes in the pathogenesis of chlamydia disease. J Infect Dis 2009, 200(September (6)):926-934.
28. Gottlieb S.L., Martin D.H., Xu F., Byrne G.I., Brunham R.C. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control. J Infect Dis 2010, 201(June (Suppl. 2)):S190-S204.
29. Hafner L., Beagley K., Timms P. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol 2008, 1(March (2)):116-130.
30. Howie S.E.M., Horner P.J., Horne A.W., Entrican G. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. Curr Opin Infect Dis 2011, 24(February (1)):56-61.
31. Miyairi I., Ramsey K.H., Patton D.L. Duration of untreated chlamydial genital infection and factors associated with clearance: review of animal studies. J Infect Dis 2010, 201(June (Suppl. 2)):S96-S103.
32. Morrison S.G., Farris C.M., Sturdevant G.L., Whitmire W.M., Morrison R.P. Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity. J Infect Dis 2011, 203(April (8)):1120-1128.
33. Batteiger B.E., Xu F., Johnson R.E., Rekart M.L. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010, 201(June (Suppl. 2)):S178-S189.
34. Starnbach M.N., Loomis W.P., Ovendale P., Regan D., Hess B., Alderson M.R., et al. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8(+) T cell response. J Immun 2003, 171(November (9)):4742-4749.
35. Farris C.M., Morrison S.G., Morrison R.P. CD4(+) T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun 2010, 78(October (10)):4374-4383.
36. Moore T., Ekworomadu C.O., Eko F.O., MacMillan L., Ramey K., Ananaba G.A., et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003, 188(August (4)):617-624.
37. Morrison S.G., Morrison R.P. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun 2000, 68(May (5)):2870-2879.
38. Villeneuve A., Brossay L., Paradis G., Hebert J. Determination of neutralizing epitopes in variable domains I and IV of the major outer-membrane protein from Chlamydia trachomatis serovar K. Microbiology 1994, 140(September (Pt 9)):2481-2487.
39. Harkinezhad T., Schautteet K., Vanrompay D. Protection of budgerigars (Melopsittacus undulatus) against Chlamydophila psittaci challenge by DNA vaccination. Vet Res 2009, 40(November (6)):61.
40. Verminnen K., Loock M.V., Cox E., Goddeeris B.M., Vanrompay D. Protection of turkeys against Chlamydophila psittaci challenge by DNA and rMOMP vaccination and evaluation of the immunomodulating effect of 1 alpha,25-dihydroxyvitamin D(3). Vaccine 2005, 23(August (36)):4509-4516.
41. Verminnen K., Beeckman D.S., Sanders N.N., De S.S., Vanrompay D.C. Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration. Vaccine 2010, 28(April (18)):3095-3105.
42. Zhang D., Yang X., Berry J., Shen C., McClarty G., Brunham R.C. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis 1997, 176(October (4)):1035-1040.
43. Zhang D.J., Yang X., Shen C., Brunham R.C. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology 1999, 96(February (2)):314-321.
44. Su H., Morrison R.P., Watkins N.G., Caldwell H.D. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J Exp Med 1990, 172(July (1)):203-212.
45. Van Loock M., Lambin S., Volckaert G., Goddeeris B.M., Vanrompay D. Influence of maternal antibodies on Chlamydophila psittaci-specific immune responses in turkeys elicited by naked DNA. Vaccine 2004, 22(April (13/14)):1616-1623.
46. Johansson E.L., Wassen L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001, 69(December (12)):7481-7486.
47. Dawson H., Reece J., Urban J. A comparative analysis of the porcine, murine, and human immune systems. 8th international veterinary immunology symposium, vol. 120 2007, [Ref Type: Abstract].
48. Nfon C.K., Dawson H., Toka F.N., Golde W.T. Langerhans cells in porcine skin. Vet Immunol Immunopathol 2008, 126(December (3/4)):236-247.
49. Gray R.T., Beagley K.W., Timms P., Wilson D.P. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009, 199(June (11)):1680-1688.
50. Melkebeek V., Verdonck F., Stuyven E., Goddeeris B., Cox E. Plasmid-encoded GM-CSF induces priming of the F4(K88)-specific serum IgA response by FaeG DNA vaccination in pigs. Vaccine 2006, 24(May (21)):4592-4594.
51. Melkebeek V., Van den B.W., Verdonck F., Goddeeris B.M., Cox E. Effect of plasmid DNA encoding the porcine granulocyte-macrophage colony-stimulating factor on antigen-presenting cells in pigs. Vet Immunol Immunopathol 2008, 125(October (3/4)):354-360.
52. Loots K., Loock M.V., Vanrompay D., Goddeeris B.M. CpG motifs as adjuvant in DNA vaccination against Chlamydophila psittaci in turkeys. Vaccine 2006, 24(May (21)):4598-4601.
53. Vanrompay D., Cox E., Kaiser P., Lawson S., Van Loock M., Volckaert G., et al. Protection of turkeys against Chlamydophila psittaci challenge by parenteral and mucosal inoculations and the effect of turkey interferon-gamma on genetic immunization. Immunology 2001, 103(May (1)):106-112.
54. Lavelle E.C., Thanavala Y., Ogra P. Mucosal immunity on the banks of the Duoro. Hum Vaccin 2009, 5(May (5)):281-283.
55. Ralli-Jain P., Tifrea D., Cheng C., Pal S., de la Maza L.M. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 2010, 28(November (48)):7659-7666.
56. McClarty G., Caldwell H.D., Nelson D.E. Chlamydial interferon gamma immune evasion influences infection tropism. Curr Opin Microbiol 2007, 10(February (1)):47-51.
57. Bielinska A.U., Yen A., Wu H.L., Zahos K.M., Sun R., Weiner N.D., et al. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials 2000, 21(May (9)):877-887.
58. Florea B.I., Meaney C., Junginger H.E., Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci 2002, 4(3):E12.
59. Sanders N.N., De Smedt S.C., Cheng S.H., Demeester J. Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus. Gene Ther 2002, 9(March (6)):363-371.
60. Wiseman J.W., Goddard C.A., McLelland D., Colledge W.H. A comparison of linear and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo. Gene Ther 2003, 10(September (19)):1654-1662.
61. Yang H., Oura C.A., Kirkham P.A., Parkhouse R.M. Preparation of monoclonal anti-porcine CD3 antibodies and preliminary characterization of porcine T lymphocytes. Immunology 1996, 88(August (4)):577-585.
62. Pescovitz M.D., Lunney J.K., Sachs D.H. Preparation and characterization of monoclonal antibodies reactive with porcine PBL. J Immunol 1984, 133(1):368-375.
63. Saalmuller A., Aasted B., Canals A., Dominguez J., Goldman T., Lunney J.K., et al. Analyses of mab reactive with porcine CD8. Vet Immunol Immunopathol 1994, 43(October (1-3)):249-254.
64. Saalmuller A. Characterization of swine leukocyte differentiation antigens. Immunol Today 1996, 17(August (8)):352-354.
65. Davis W.C., Zuckermann F.A., Hamilton M.J., Darbosa J.I., Saalmuller A., Binns R.M., et al. Analysis of monoclonal antibodies that recognize gamma delta T/null cells. Vet Immunol Immunopathol 1998, 60(January (3/4)):305-316.
66. Lunney J.K., Walker K., Goldman T., Aasted B., Bianchi A., Binns R., et al. Overview of the first international workshop to define swine leukocyte cluster of differentiation (CD) antigens. Vet Immunol Immunopathol 1994, 43(October (1-3)):193-206.